Hattori T, Nimoto M, Yamagata S, Tohge T
Jpn J Surg. 1975 Sep;5(3):133-8. doi: 10.1007/BF02469393.
Streptococcal preparation (OK-432), a new type of anti-cancer agent, was given to the patients with advanced cancer in combination with Mitomycin-C, 5-FU and Cytosine arabinoside. OK-432 was administered intramuscularly with a daily dose of 2.0 KE consecutively or locally into the tumor with a large-dose of 100 KE. Most cases tolerated the long term administration of OK-432 without any severe side effects and the highest dose reached was 314 KE during 161 days of treatment. Of the 53 patients evaluated, 31 were given the initial large dose intratumoral OK-432. Thirteen were judged 0-C and Category 1 according to the Karnofsky criteria for a response rate of 44.8 per cent as compared with 12.5 per cent in the group without the initial large-dose administration.
链球菌制剂（OK - 432）是一种新型抗癌药物，用于晚期癌症患者，并与丝裂霉素 - C、5 - 氟尿嘧啶和阿糖胞苷联合使用。OK - 432通过肌肉注射给药，每日剂量为2.0KE，连续给药，或大剂量100KE局部注射到肿瘤内。大多数病例耐受OK - 432的长期给药，无任何严重副作用，在161天的治疗期间，最高剂量达到314KE。在评估的53例患者中，31例接受了肿瘤内初始大剂量OK - 432治疗。根据卡诺夫斯基标准，13例被判定为0 - C和1级，有效率为44.8%，而未进行初始大剂量给药的组有效率为12.5%。
